Vanguard Group Inc. Acquires 156,679 Shares of Revvity, Inc. (NYSE:RVTY)

Vanguard Group Inc. boosted its holdings in shares of Revvity, Inc. (NYSE:RVTY) by 1.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,290,211 shares of the company’s stock after acquiring an additional 156,679 shares during the quarter. Vanguard Group Inc. owned 11.74% of Revvity worth $1,594,930,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of RVTY. Assetmark Inc. boosted its stake in shares of Revvity by 3,700.0% during the fourth quarter. Assetmark Inc. now owns 266 shares of the company’s stock valued at $30,000 after purchasing an additional 259 shares during the period. Continuum Advisory LLC lifted its holdings in Revvity by 2,972.7% during the 3rd quarter. Continuum Advisory LLC now owns 338 shares of the company’s stock valued at $43,000 after buying an additional 327 shares in the last quarter. Millstone Evans Group LLC bought a new stake in Revvity during the 4th quarter valued at about $38,000. MassMutual Private Wealth & Trust FSB boosted its position in Revvity by 55.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 385 shares of the company’s stock valued at $43,000 after buying an additional 138 shares during the period. Finally, EverSource Wealth Advisors LLC grew its stake in Revvity by 33.5% in the 4th quarter. EverSource Wealth Advisors LLC now owns 522 shares of the company’s stock worth $58,000 after acquiring an additional 131 shares in the last quarter. Institutional investors own 86.65% of the company’s stock.

Revvity Stock Up 0.0 %

Shares of Revvity stock opened at $107.41 on Friday. Revvity, Inc. has a 52-week low of $97.32 and a 52-week high of $129.50. The firm’s 50 day moving average price is $115.42 and its 200-day moving average price is $117.28. The company has a quick ratio of 3.03, a current ratio of 3.60 and a debt-to-equity ratio of 0.41. The company has a market cap of $12.90 billion, a P/E ratio of 48.60, a PEG ratio of 3.82 and a beta of 1.06.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Friday, January 31st. The company reported $1.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same quarter in the prior year, the firm earned $1.25 EPS. On average, sell-side analysts predict that Revvity, Inc. will post 4.94 EPS for the current fiscal year.

Revvity Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 9th. Shareholders of record on Friday, April 18th will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.26%. The ex-dividend date is Thursday, April 17th. Revvity’s dividend payout ratio (DPR) is presently 12.67%.

Insider Buying and Selling at Revvity

In related news, insider Joel S. Goldberg sold 15,170 shares of the firm’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $126.73, for a total value of $1,922,494.10. Following the completion of the transaction, the insider now owns 33,400 shares in the company, valued at $4,232,782. This trade represents a 31.23 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Tajinder S. Vohra sold 5,492 shares of Revvity stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $116.81, for a total value of $641,520.52. Following the sale, the insider now directly owns 19,652 shares of the company’s stock, valued at approximately $2,295,550.12. This represents a 21.84 % decrease in their position. The disclosure for this sale can be found here. 0.68% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. KeyCorp lifted their price target on shares of Revvity from $132.00 to $145.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. Raymond James reissued an “outperform” rating and set a $145.00 price target (up previously from $140.00) on shares of Revvity in a research report on Monday, February 3rd. Bank of America upgraded Revvity from a “neutral” rating to a “buy” rating and set a $138.00 price objective for the company in a report on Friday, December 13th. Sanford C. Bernstein downgraded shares of Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 target price on the stock. in a research report on Friday, January 10th. Finally, Barclays upped their price target on shares of Revvity from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Revvity has a consensus rating of “Moderate Buy” and a consensus target price of $136.25.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.